The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
To determine whether Medicare covers CAR-T it might soon be important to find out how patients feel.